Related Experiment Video
Updated: Jan 13, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Denosumab as a treatment for pediatric hypercalcemia-a multicenter experience
Annabelle Hobbs1,2, Rishi Nair2, Karissa Ludwig1,3,4
1Department of Endocrinology and Diabetes, Queensland Children's Hospital, South Brisbane 4101, Australia.
Denosumab effectively manages pediatric hypercalcemia from various causes, including malignancy. This study shows its safety and efficacy in children when other treatments fail or bisphosphonates are contraindicated.
Area of Science:
- Pediatric Endocrinology
- Oncology
- Nephrology
Background:
- Denosumab, a monoclonal antibody targeting receptor activator of NF-κB ligand (RANKL), is established for hypercalcemia management in adults.
- Its use in pediatric hypercalcemia is not well-documented, necessitating further investigation.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion

